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Recap of Influenza Session, February 2019
 Updates on 2018-19 U.S. influenza season surveillance and preliminary vaccine 
effectiveness estimates
 Presentation from Seqirus of results of a Phase III Randomized Observer-Blind 
Comparator-Controlled study of Afluria Quadrivalent for Children 6 through 59 
months
 Presentation of a Case-Control Study of Inactivated Influenza Vaccine and 
Spontaneous Abortion in the Vaccine Safety Datalink, performed during the 2012-
13, 2013-14, and 2014-15 influenza seasons
Work Group Discussions Since February 2019
 2018-19 U.S. influenza vaccine effectiveness updates
 Discussion of influenza vaccine safety surveillance activities
 Development of 2019-20 influenza vaccine statement
– No substantial changes in language proposed
Agenda Overview





Ms. Lynnette Brammer, CDC/NCIRD
 Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness
Dr. Brendan Flannery, CDC/NCIRD
 End-of-season Update: 2018-2019 Influenza Vaccine Safety Monitoring
Dr. Tom Shimabukuro, CDC/NCEZID
 Work Group Considerations and Proposed Recommendations for 2019-20
Dr. Lisa Grohskopf, CDC/NCIRD
